GLP2R
Glucagon-like peptide 2 receptor
As of the edition of 20 October 2026, GLP2R (glucagon-like peptide 2 receptor, UniProt O95838) has 3 drugs tested at it and 3 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O95838
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Digestive system; Nutrition and metabolism; Immune system; Blood and lymph; Cancer; Heart and blood vessels; Mouth and teeth; Pregnancy and women's health
- Registered trials of its drugs
- 42
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Teduglutide | Marketed | Phase 4 | Ended 2026 |
| FE 203799 | Went quiet | Phase 2 | none listed |
| Elsiglutide | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Takeda | Route B |
| GlyPharma Therapeutics | Route A |
| Helsinn Healthcare | Route A |
The other 0 companies at GLP2R
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at GLP2R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.